Colorectal Cancer

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist at Rocky Mountain Cancer Centers, discusses the use of circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC).

Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses the prognostic value of Immunoscore in stage III colorectal cancer.

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the BEACON CRC trial in patients with BRAF V600E-mutated metastatic colorectal cancer.

Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.

Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist, Rocky Mountain Cancer Centers, discusses treatment options for left- and right-sided colorectal cancer.

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses methods of locoregional therapy in metastatic colorectal cancer.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses considerations for locoregional therapy versus resection in patients with colorectal cancer.

The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.